We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$647M
AUM Growth
-$194M
Cap. Flow
+$33.7M
Cap. Flow %
5.2%
Top 10 Hldgs %
63.34%
Holding
208
New
51
Increased
38
Reduced
42
Closed
71

Sector Composition

Rank Sector Weight
1 Miscellaneous 73.46%
2 Healthcare 26.22%
3 Consumer Staples 0.17%
4 Financials 0.05%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CARM
151
DELISTED
Carisma Therapeutics
CARM
-61,306
Closed -$2.7M
FOCL
152
EDAP TMS S.A.
FOCL
$188M
-60,600
Closed -$141K
FOCL
153
PUT
EDAP TMS S.A.
FOCL
$188M
-1,008
Closed -$234K
KYNB
154
CALL
Kyntra Bio
KYNB
$31.7M
-5
Closed -$522K
GALT icon
155
PUT
Galectin Therapeutics
GALT
$368M
-210
Closed -$100K
CBIO
156
Crescent Biopharma
CBIO
$702M
-516
Closed -$838K
HALO icon
157
Halozyme
HALO
$12.1B
-102
Closed -$2K
IMNN icon
158
Imunon
IMNN
$8.08M
-1,890
Closed -$828K
INCY icon
159
CALL
Incyte
INCY
$24.7B
-1,140
Closed -$9.5M
MNKD icon
160
CALL
MannKind Corp
MNKD
$1.15B
-1,000
Closed -$228K
MNKD icon
161
MannKind Corp
MNKD
$1.15B
-201,908
Closed -$378K
MRK icon
162
CALL
Merck
MRK
$355B
-2,610
Closed -$13.6M
MRK icon
163
Merck
MRK
$355B
-7,193
Closed -$374K
MRK icon
164
PUT
Merck
MRK
$355B
-126
Closed -$654K
FEED
165
ENvue Medical Inc
FEED
$854K
-3
Closed -$408K
OEF icon
166
PUT
iShares S&P 100 ETF
OEF
$20.1B
-2,875
Closed -$43.7M
PLUR icon
167
Pluri
PLUR
$14.1M
-346
Closed -$36.2K
PRPO icon
168
Precipio
PRPO
$49.2M
-2,548
Closed -$411K
PRQR icon
169
ProQR Therapeutics
PRQR
$257M
-172,160
Closed -$529K
PRTA icon
170
CALL
Prothena Corp
PRTA
$429M
-240
Closed -$74K
PRTA icon
171
Prothena Corp
PRTA
$429M
-24,500
Closed -$899K
PRTA icon
172
PUT
Prothena Corp
PRTA
$429M
-431
Closed -$1.34M
PTCT icon
173
CALL
PTC Therapeutics
PTCT
$5.48B
-1,475
Closed -$84K
PULM icon
174
Pulmatrix
PULM
$5.3M
-5,438
Closed -$554K
SLDB icon
175
Solid Biosciences
SLDB
$907M
-1,667
Closed -$188K

Similar funds

Sabby Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sabby Management held 208 positions worth $647M, down 23% from $841M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $33.7M of net new capital in Q2 2018, opening 51 new positions and adding to 38 existing holdings. Its largest new stake was Novo Nordisk: 858,710 shares worth $19.8M.

By sector, the portfolio is most concentrated in Miscellaneous at 73% of assets, down from 83% a quarter earlier, followed by Healthcare and Consumer Staples.

On the sell side, the largest reduction was Biogen, an estimated $8.66M trimmed.

  • Sabby Management's largest Q2 2018 buy was Novo Nordisk: 858,710 shares worth $19.8M.
  • Sabby Management added most to Nektar Therapeutics in Q2 2018, an estimated $14.1M increase.
  • Sabby Management's biggest Q2 2018 reduction was Biogen, cutting an estimated $8.66M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2018, selling an estimated $12M.
  • Sabby Management's ten largest holdings make up 63% of its $647M portfolio in Q2 2018.
  • Sabby Management opened 51 new positions and closed 71 in Q2 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $647M.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.